Novo Nordisk: Company Did Not Report or Investigate Deaths Potentially Caused by Ozempic

Published on Jul 15, 2025

Novo Nordisk (NVO) did not report multiple deaths that may have been caused by its blockbuster weight loss drug Ozempic to the FDA, according to an agency inspection report obtained by The Capitol Forum through a Freedom of Information Act request… The rest of this article is currently locked and only available to subscribers. Request […]

The rest of this article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

Medline: In Rare Move, FDA Revokes Regulatory Approval for Several Medical Devices Sold by Company

The FDA has revoked the regulatory approvals for several medical devices sold by Medline (MDLN), according to recent updates on the agency’s recall database. 22 Medline devices and kits are being...

Apr 24, 2026 Read Now >

House Judiciary Panel Counsel Cella, Paul Hastings Partner Murray Emerge as Early Contenders to Become DOJ Antitrust Head

Adam Cella, a senior House GOP counsel, and Michael Murray, who served at DOJ during President Donald Trump’s first term, have emerged as early contenders to take over the department’s antitrust...

Apr 20, 2026 Read Now >

Private Equity Investment in Clinical Trial Sites Raises Potential Antitrust, CPOM Concerns

Private equity’s growing interest in clinical trial sites and services raises questions about how increased consolidation will impact the cost and sustainability of pharmaceutical research and...

Apr 17, 2026 Read Now >

Novo Nordisk: Company Did Not Report or Investigate Deaths Potentially Caused by Ozempic

RELATED ARTICLES | Editor’s picks

Medline: In Rare Move, FDA Revokes Regulatory Approval for Several Medical Devices Sold by Company

House Judiciary Panel Counsel Cella, Paul Hastings Partner Murray Emerge as Early Contenders to Become DOJ Antitrust Head

Private Equity Investment in Clinical Trial Sites Raises Potential Antitrust, CPOM Concerns

FILTER BY